Recently, we experienced a rare case of Budd-Chiari Syndrome. The case was a 57-year-old female patient. Venous return had been severely disturbed by the membranous occlusion of the IVC and a giant fl oating thrombus. After catheter directed thrombolysis combined with stepwise percutaneous angioplasty, the IVC was recanalized suffi ciently and the thrombus was completely resolved.
Introduction
Major pathophysiological feature of Budd-Chiari syndrome (BCS) in Asian countries is portal and inferior vena cava (IVC) hypertension resulting from membranous obstruction. 1, 2) Endovascular approaches have been successfully used to treat the BCS, but concomitant thrombosis in the IVC precluded the standard procedure due to the risk of pulmonary embolism. Recently, we experienced an endovascular treatment for such a rare case of BCS. We report the clinical course, and describe the backgrounds of procedures.
Case Report
The case was a 57-year-old female patient. She had an endovascular procedure for BCS about 10 years ago, when the suprahepatic membranous obstruction of IVC was recanalized with balloon angioplasty. She had been on an anticoagulation therapy, but it was abandoned with unknown reasons. The main hepatic veins had been obstructed before the initial procedure, but the two inferior short hepatic veins had been developed instead as main collateral vessels. When she was referred to us, she had complained of severe abdominal fullness and lower extremity edema. The recent endoscopic study did not fi nd any critically worsening signs of esophageal varices. Contrast computed tomography (CT) found the reformation of membranous obstruction at the suprahepatic IVC, thrombotic obstruction in one of the major collateral vessels, a formation of large IVC thrombus, and moderate amount of ascites. We recommended emergent endovascular procedure, but the patient refused taking any treatments. A month later, she came back to us with the worsening symptoms. This time, we found the further growth of the thrombus in the obstructed IVC (Fig. 1A and 1B) , and an increased amount of ascites. USA), the caval fl ow through the lesion was restored to the dominant venous return to the right atrium. This time, another temporary IVC fi lter could be easily inserted from the jugular vein access, and located caudally to the membranous obstruction (Fig. 2C) . A thrombolytic catheter with side holes (Fountain; Meritmedical, Utah, USA) was inserted from the right femoral vein (Fig. 2D) . Through the catheter, urokinase (60000 unit) was injected in every 12 hours. A week after the treatment, the thrombus found partially resolved. Two weeks after the start of the injection, the fl oating thrombus became unrecognized by IVC-DSA ( Fig. 2E and 2F) . The temporarily IVC fi lter was exchanged, and the lesion was further dilated using 15 and 20 mm balloon (Maxi LD; Johnson and Johnson, New Jersey, USA). The thrombolytic catheter the experience of Ding and colleagues, 3) we tried to treat her with a combination of thrombolytic therapy and balloon dilatation. At the time of procedure, the large thrombus was found to be fl oating inside the IVC (Fig. 1C and 1D) . The obstruction could be traversed through the right femoral approach (Fig. 2A) . A temporary IVC fi lter (Neuhaus Protect; Toray Medical, Chiba, Japan) was tried to be inserted from the jugular access, but it could not be passed through the obstruction. Then, the fi lter was inserted from the left femoral vein, initially. A 5 mm balloon (Rival; Bard Peripheral Vascular, Tempe, Arizona, USA), traversed through the obstruction from the right femoral access, was carefully infl ated to recanalize the membranous portion (Fig. 2B) . After further dilatation using a 10 mm balloon (Fox Cross; Abbott, Illinois, Budd Chiari Syndrome with IVC Thrombosis and lower extremity edema, had gradually disappeared. The patency of IVC has been maintained for about a year (Fig. 3) .
Endovascular procedure

Discussion
The caval fl ow stasis could be a cause of activating coagulation pathway, and thrombus in the IVC was found about 20% of BCS cases. 4) Most of these cases present to hospitals in chronic stages, because onset was removed, and the injection of urokinase was terminated. The patient had started to be on another anticoagulant therapy using Coumadin, and the international normalized ratio of prothrombin time was increased over 3.0. Three weeks from the start of treatment, after the reconfi rmation of the disappearance of thrombus by contrast CT, the fi lter was removed, and continuous injection of heparin was fi nished. After the start of treatments, the congestive symptoms, including abdominal fullness, dyspnea, 
the risk of PE by the use of IVC fi lters and stepwise angioplasty under these circumstances. There may be concerns about the use of permanent IVC fi lters and their effi ciency. The use of retrievable type of fi lters under the strictly controlled anticoagulation therapy should reduce the risks of fi lter related problems. 8) As aforementioned, blood fl ow through the thrombosed vein was maintained to enhance the effi ciency of thrombolysis. The occlusion was fi rstly opened to a degree that the caval venous return through the fi lter-protected IVC, not through the collateral vessels, became dominant. Angioplasty using up to 10 mm PTA balloon was suffi cient for that purpose. Dominancy in fl ow could be recognized by the fl ow pattern of digitally subtracted angiography. Secondary dilatation up to the use of 20 mm balloon was performed after the thrombus could not be recognized in the IVC. Otherwise, though temporarily, total occlusion of the IVC might increase the large collateral venous return, and thus might have increased the risk of PE.
Considering the risk of restenosis or occlusion, metallic stent might be placed to maintain the patency. Bare or covered 9) stents may help to compress the remaining mural thrombus and serve to prevent PE. However, the post-procedural CT showed no remnant of the disease seemed often asymptomatic. 5) This may explain why precise information about the age or form of IVC thrombi has been limited. BCS with such a giant fl oating thrombus could not be found in our literature search. Speculatively, the thrombus should have been initially formed as a large caval thrombus after re-obstruction of the IVC. Thrombectomy under cardiopulmonary bypass, 6) and ultimately for far advanced liver failure cases, liver transplantation would remain other treatment options. However, these are highly invasive procedures for symptomatic BCS cases. 7) Therefore, endovascular method may be the fi rst treatment option under these circumstances.
Fatal pulmonary emboli (PE) resulting from dislodgement of thrombotic materials from the IVC had been one of the major concerns for thrombolysis, especially to deal with such a case. While the rigorous contact of the thrombolytic agent to the thrombus might intensify thrombolytic effects, the catheter directed thrombolysis might also increase the risk of PE. On the other hand, especially for the chronic thrombus, maintenance of blood fl ow through the thrombosed vein appeared critical to success of the procedure. 3) These two concepts (to maintain a sufficient caval fl ow and to prevent pulmonary embolism), thus contradicted to each other. We tried to minimize thrombus in the IVC, and the patency has been excellently maintained. It has been reported that approximately 13% of patients who underwent stent placement had re-stenosis develop due to tissue hyperplasia. 10) Therefore, metallic stent has not been used in the present case. There were several different endovascular options for treating the caval thrombus. The use of other devices, such as rheolytic or mechanical thrombectomy catheter, although there still remains problem of effi ciency in collecting the debris, might be feasible for further reduction of risk of PE. For the prevention of recurrent IVC thrombosis, the PT-INR has been kept around 3. From the viewpoint of risk-management for gastro-intestinal bleeding, keeping such a high level of PT-INR may be controversial. Anti-platelet drugs have not been used for the patient, concerning diffi culties for emergent correction of the drug effects.
